Drug Insight: Aminosalicylates for the treatment of IBD

Research output: Contribution to journal › Review › Research › peer-review

Standard

Drug Insight : Aminosalicylates for the treatment of IBD. / Nielsen, Ole H.; Munck, Lars K.

In: Nature Clinical Practice Gastroenterology and Hepatology, Vol. 4, No. 3, 01.03.2007, p. 160-170.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Nielsen, OH & Munck, LK 2007, 'Drug Insight: Aminosalicylates for the treatment of IBD', Nature Clinical Practice Gastroenterology and Hepatology, vol. 4, no. 3, pp. 160-170. https://doi.org/10.1038/ncpgasthep0696

APA

Nielsen, O. H., & Munck, L. K. (2007). Drug Insight: Aminosalicylates for the treatment of IBD. Nature Clinical Practice Gastroenterology and Hepatology, 4(3), 160-170. https://doi.org/10.1038/ncpgasthep0696

Vancouver

Nielsen OH, Munck LK. Drug Insight: Aminosalicylates for the treatment of IBD. Nature Clinical Practice Gastroenterology and Hepatology. 2007 Mar 1;4(3):160-170. https://doi.org/10.1038/ncpgasthep0696

Author

Nielsen, Ole H. ; Munck, Lars K. / Drug Insight : Aminosalicylates for the treatment of IBD. In: Nature Clinical Practice Gastroenterology and Hepatology. 2007 ; Vol. 4, No. 3. pp. 160-170.

Bibtex

@article{1510cefdb619407686a2f5d20355fba8,
title = "Drug Insight: Aminosalicylates for the treatment of IBD",
abstract = "Sulfasalazine and mesalazine (also known as mesalamine; 5-aminosalicylic acid) preparations have for many years been used for the treatment of IBD (i.e. ulcerative colitis and Crohn's disease), for both active disease and the control of remission. It has also been suggested that mesalazine is a chemoprophylactic agent that protects against the development of colorectal cancer. This Review focuses on the latest clinical evidence for the use of these aminosalicylates for the treatment of IBD, and concludes that sulfasalazine and mesalazine are useful for the treatment of both active and quiescent ulcerative colitis, whereas they have no clinical effect on either active or inactive Crohn's disease. Furthermore, evidence is lacking that mesalazine per se is a chemoprophylactic agent.",
author = "Nielsen, {Ole H.} and Munck, {Lars K.}",
year = "2007",
month = mar,
day = "1",
doi = "10.1038/ncpgasthep0696",
language = "English",
volume = "4",
pages = "160--170",
journal = "Nature Clinical Practice Gastroenterology & Hepatology",
issn = "1743-4378",
publisher = "nature publishing group",
number = "3",

}

RIS

TY - JOUR

T1 - Drug Insight

T2 - Aminosalicylates for the treatment of IBD

AU - Nielsen, Ole H.

AU - Munck, Lars K.

PY - 2007/3/1

Y1 - 2007/3/1

N2 - Sulfasalazine and mesalazine (also known as mesalamine; 5-aminosalicylic acid) preparations have for many years been used for the treatment of IBD (i.e. ulcerative colitis and Crohn's disease), for both active disease and the control of remission. It has also been suggested that mesalazine is a chemoprophylactic agent that protects against the development of colorectal cancer. This Review focuses on the latest clinical evidence for the use of these aminosalicylates for the treatment of IBD, and concludes that sulfasalazine and mesalazine are useful for the treatment of both active and quiescent ulcerative colitis, whereas they have no clinical effect on either active or inactive Crohn's disease. Furthermore, evidence is lacking that mesalazine per se is a chemoprophylactic agent.

AB - Sulfasalazine and mesalazine (also known as mesalamine; 5-aminosalicylic acid) preparations have for many years been used for the treatment of IBD (i.e. ulcerative colitis and Crohn's disease), for both active disease and the control of remission. It has also been suggested that mesalazine is a chemoprophylactic agent that protects against the development of colorectal cancer. This Review focuses on the latest clinical evidence for the use of these aminosalicylates for the treatment of IBD, and concludes that sulfasalazine and mesalazine are useful for the treatment of both active and quiescent ulcerative colitis, whereas they have no clinical effect on either active or inactive Crohn's disease. Furthermore, evidence is lacking that mesalazine per se is a chemoprophylactic agent.

UR - http://www.scopus.com/inward/record.url?scp=33847707327&partnerID=8YFLogxK

U2 - 10.1038/ncpgasthep0696

DO - 10.1038/ncpgasthep0696

M3 - Review

C2 - 17339853

AN - SCOPUS:33847707327

VL - 4

SP - 160

EP - 170

JO - Nature Clinical Practice Gastroenterology & Hepatology

JF - Nature Clinical Practice Gastroenterology & Hepatology

SN - 1743-4378

IS - 3

ER -

ID: 218707483